Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf063 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von David Malnoë und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes 35033, France. Hauptthemen laut MEDLINE: Cyclosporine, Hematopoietic Stem Cell Transplantation, Acetates, Quinazolines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Objectives
Letermovir, a cytomegalovirus prophylactic agent, is widely used in allogeneic HSCT recipients. As an inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), it may interact with ciclosporin A (CsA), potentially impacting its pharmacokinetics. Inflammation can impair CYP3A-mediated drug metabolism, with severe inflammation reducing CsA metabolism. However, current data on the drug–drug interaction (DDI) between CsA and letermovir as a perpetrator are limited to healthy volunteers and lack evaluation in HSCT patients, particularly under minimal inflammation conditions, where such DDIs may occur.
Methods
This retrospective, observational, single-centre study included seven adult HSCT recipients who received CsA and letermovir concurrently with no-to-mild inflammation (C-reactive protein ≤40 mg/L). CsA concentration/dose (C/D) ratios were calculated before and after letermovir initiation. Changes in CsA pharmacokinetics were analysed using Wilcoxon signed-rank tests.
Results
A 240 mg dose of letermovir once daily significantly increased the median CsA C/D ratio from 0.39 to 0.90 (P = 0.0156) and the median CsA trough concentration from 136 µg/L to 240 µg/L (P = 0.0156). These changes were attributed to CYP3A4 inhibition by letermovir, given the stable no-to-mild inflammatory status and the lack of additional DDI.
Conclusion
Letermovir significantly decreased CsA metabolism in HSCT patients through CYP3A4 inhibition, with clinical implications for dosing precision. Close therapeutic drug monitoring (generally twice weekly) is therefore recommended during letermovir initiation and discontinuation to mitigate risks of subtherapeutic levels or toxicity. This study highlights the significance of assessing DDIs in HSCT, where inflammation modulates metabolic interactions resulting in a complex interplay such as a disease–drug–drug interaction (D–DDI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes 35033, France.
- Faculté de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Université de Rennes, Rennes 35043, France.
- CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Université Rennes, Rennes F-35000, France.
- CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, Rennes 35000, France.
- Service d'Hématologie Clinique, CHU de Rennes, INSERM U1236, Université de Rennes, Rennes 35000, France.
ORCID-Profile: David Malnoë, Mathilde Bories, Tony Marchand, Pascal Le Corre
Zitieren
APA
Malnoë, D., Bories, M., Marchand, T., & Le Corre, P. (2025). Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf063
Vancouver
Malnoë D, Bories M, Marchand T, Le Corre P. Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf063
BibTeX
@article{Malno2025,
author = {Malnoë, David and Bories, Mathilde and Marchand, Tony and Le Corre, Pascal},
title = {Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf063}
}
EUVIMED